Soleno Therapeutics Inc. (NASDAQ:slno)yes The best performing Zhongcai stocks so far in 2025. On July 10, Soleno Therapeutics announced that sales of its new Prader-Willi virus, known as Vykat XR, exceeded Wall Street expectations. Vykat XR is the first approved treatment for infinite hunger associated with Prader-Willi syndrome and was approved in the United States on March 26 this year.
Soleno expects net revenue from Vykat XR sales to be between $31 and $33 million in the three months ended June 30. Since approval, the company has received about 646 “start forms” from 295 doctors who have shown strong initial demand. Although quarterly performance reviews are underway and estimates are likely to change, Stifel analyst James Condulis noted that these preliminary figures are investors’ expectations.
Biopharmaceutical product range on laboratory shelves waiting for testing on laboratory shelves.
Prader-Willi syndrome is a rare genetic disease with an estimated 10,000 to 20,000 people in the United States, characterized by behavioral and cognitive symptoms, most notably a full-time-consuming hunger (female). Prior to Vykat XR, the management of the disease often involved supportive care and human growth hormone.
Soleno Therapeutics Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutic therapies to treat rare diseases.
Although we acknowledge the potential of SLNO as an investment, we believe that certain AI stocks have greater upside potential and smaller downside risks. If you are looking for an undervalued AI stock that will also benefit greatly from the Trump era tariffs and open trends, see our related free reports Best Short-term AI Stocks.
Read the next article: 30 shares should double within 3 years and 11 Hidden AI Stocks Buy Now.
Disclosure: None. This article was originally published in Internal monkey.
